P21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Mergui, Xénia ^a   Puiffe, Marie Line ^a   Valteau Couanet, Dominique ^a   Lipinski, Marc ^a   Bénard, Jean ^a   Amor Guéret, Mounira ^b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; SMALL INTERFERING RNA; VIMENTIN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMEDIATE FILAMENT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; OVERALL SURVIVAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; ADOLESCENT; CHILD; DRUG ANTAGONISM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; INFANT; MALE; METABOLISM; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL RATE; TUMOR CELL CULTURE;

ADOLESCENT; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; VIMENTIN;

EID: 77956470083     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-473     Document Type: Article

References (22)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007, 369(9579):2106-2120. 10.1016/S0140-6736(07)60983-0, 17586306.
2. Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, Rubie H, Coze C, Plantaz D, Bernard F, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005, 23(3):532-540. 10.1200/JCO.2005.03.054, 15659499.
3. Thiele C. Neuroblastoma Cell Lines. 1998, 1. Lancaster, UK: Kluwer Academic Publishers.
4. Mergui X, Leteurtre F, Lipinski M, Benard J, Amor-Gueret M. Two distinctly altered cellular responses to DNA double-strand breaks in human neuroblastoma. Biochimie 2008, 90(11-12):1656-1666. 10.1016/j.biochi.2008.06.008, 18627787.
5. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 2007, 313(10):2050-2062. 10.1016/j.yexcr.2007.03.040, 17512929.
6. Traub P, Mothes E, Shoeman R, Kuhn S, Scherbarth A. Characterization of the nucleic acid-binding activities of the isolated amino-terminal head domain of the intermediate filament protein vimentin reveals its close relationship to the DNA-binding regions of some prokaryotic single-stranded DNA-binding proteins. J Mol Biol 1992, 228(1):41-57. 10.1016/0022-2836(92)90490-B, 1447793.
7. Tolstonog GV, Mothes E, Shoeman RL, Traub P. Isolation of SDS-stable complexes of the intermediate filament protein vimentin with repetitive, mobile, nuclear matrix attachment region, and mitochondrial DNA sequence elements from cultured mouse and human fibroblasts. DNA Cell Biol 2001, 20(9):531-554. 10.1089/104454901317094954, 11747605.
8. Li G, Tolstonog GV, Sabasch M, Traub P. Type III intermediate filament proteins interact with four-way junction DNA and facilitate its cleavage by the junction-resolving enzyme T7 endonuclease I. DNA Cell Biol 2003, 22(4):261-291. 10.1089/104454903321908656, 12823903.
9. Benard J, Raguenez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, et al. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2008, 2(3):261-271. 10.1016/j.molonc.2008.07.002, 19383347.
10. Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E, Reisdorf P. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 2000, 275(6):3867-3872. 10.1074/jbc.275.6.3867, 10660538.
11. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002, 179(1):1-14. 10.1016/S0304-3835(01)00847-3, 11880176.
12. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005, 23(10):2280-2299. 10.1200/JCO.2005.06.104, 15800319.
13. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27(7):1026-1033. 10.1200/JCO.2008.16.0630, 19171713.
14. Hartig R, Shoeman RL, Janetzko A, Tolstonog G, Traub P. DNA-mediated transport of the intermediate filament protein vimentin into the nucleus of cultured cells. J Cell Sci 1998, 111(Pt 24):3573-3584.
15. Goehler H, Lalowski M, Stelzl U, Waelter S, Stroedicke M, Worm U, Droege A, Lindenberg KS, Knoblich M, Haenig C, et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol Cell 2004, 15(6):853-865. 10.1016/j.molcel.2004.09.016, 15383276.
16. Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker DK, Solimando L, Goldman RD. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev 2008, 22(7):832-853. 10.1101/gad.1652708, 2732390, 18381888.
17. Miralles F, Visa N. Actin in transcription and transcription regulation. Curr Opin Cell Biol 2006, 18(3):261-266. 10.1016/j.ceb.2006.04.009, 16687246.
18. Lee DC, Welton KL, Smith ED, Kennedy BK. A-type nuclear lamins act as transcriptional repressors when targeted to promoters. Exp Cell Res 2009, 315(6):996-1007. 10.1016/j.yexcr.2009.01.003, 2746445, 19272320.
19. Helfand BT, Chou YH, Shumaker DK, Goldman RD. Intermediate filament proteins participate in signal transduction. Trends Cell Biol 2005, 15(11):568-570. 10.1016/j.tcb.2005.09.009, 16213139.
20. Boyne LJ, Fischer I, Shea TB. Role of vimentin in early stages of neuritogenesis in cultured hippocampal neurons. Int J Dev Neurosci 1996, 14(6):739-748. 10.1016/S0736-5748(96)00053-6, 8960981.
21. Shea TB, Beermann ML, Fischer I. Transient requirement for vimentin in neuritogenesis: intracellular delivery of anti-vimentin antibodies and antisense oligonucleotides inhibit neurite initiation but not elongation of existing neurites in neuroblastoma. J Neurosci Res 1993, 36(1):66-76. 10.1002/jnr.490360108, 8230322.
22. Wainwright LJ, Lasorella A, Iavarone A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc Natl Acad Sci USA 2001, 98(16):9396-9400. 10.1073/pnas.161288698, 55432, 11481496.